RMD · Resmed Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B |
| Cost of Revenue | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B |
| Gross Profit | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B |
| R&D | $331.28M | $307.52M | $287.64M | $253.57M | $225.28M | $201.95M |
| SG&A | $991.02M | $917.14M | $874.00M | $739.37M | $670.39M | $676.69M |
| Total Operating Expenses | $1.37B | $1.34B | $1.22B | $1.02B | $935.42M | $908.13M |
| D&A | $198.47M | $176.87M | $165.16M | $159.61M | $156.76M | $154.85M |
| Operating Income | $1.69B | $1.32B | $1.13B | $1.00B | $903.68M | $809.66M |
| Interest Expense | - | - | - | - | $23.99M | $40.38M |
| Income Tax | $276.84M | $243.85M | $204.11M | $181.05M | $409.16M | $111.41M |
| Net Income | $1.40B | $1.02B | $897.56M | $779.44M | $474.50M | $621.67M |
| EPS - Basic | $9.55 | $6.94 | $6.12 | $5.34 | $3.27 | $4.31 |
| EPS - Diluted | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.21B | $238.36M | $227.89M | $273.71M | $295.28M | $463.16M |
| Accounts Receivable | $939.49M | $837.27M | $704.91M | $575.95M | $614.29M | $474.64M |
| Inventory | $927.71M | $822.25M | $998.01M | $743.91M | $457.03M | $416.92M |
| Accounts Payable | $278.16M | $237.73M | $150.76M | $159.25M | $138.01M | $135.79M |
| Current Assets | $3.51B | $2.36B | $2.37B | $1.93B | $1.57B | $1.52B |
| Total Assets | $8.17B | $6.87B | $6.75B | $5.10B | $4.73B | $4.59B |
| Current Liabilities | $1.02B | $910.65M | $758.53M | $689.30M | $911.77M | $602.76M |
| Long-term Debt | $658.39M | $697.31M | $1.43B | $765.33M | $643.35M | $1.16B |
| Total Liabilities | $2.21B | $2.01B | $2.62B | $1.74B | $1.84B | $2.09B |
| Stockholders' Equity | $5.97B | $4.86B | $4.13B | $3.36B | $2.89B | $2.50B |
| Retained Earnings | $6.08B | $4.99B | $4.25B | $3.61B | $3.08B | $2.83B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.75B | $1.40B | $693.30M | $351.15M | $736.72M | $802.25M |
| Investing Cash Flow | ($200.04M) | ($269.78M) | ($1.16B) | ($229.92M) | ($158.46M) | ($179.86M) |
| Financing Cash Flow | ($606.25M) | ($1.12B) | $422.87M | ($128.36M) | ($764.63M) | ($317.29M) |
| CapEx | $89.86M | $99.46M | $119.67M | $134.84M | $102.71M | $95.33M |
| Free Cash Flow | $1.66B | $1.30B | $573.63M | $216.31M | $634.01M | $706.92M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% | 58.1% |
| Operating margin | 32.7% | 28.2% | 26.8% | 28.0% | 28.3% | 27.4% |
| EBITDA margin | 36.6% | 31.9% | 30.7% | 32.4% | 33.2% | 32.6% |
| Net margin | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% | 21.0% |
| Free cash flow margin | 32.3% | 27.8% | 13.6% | 6.0% | 19.8% | 23.9% |
| FCF / Net income | 1.19 | 1.28 | 0.64 | 0.28 | 1.34 | 1.14 |
| R&D / Revenue | 6.4% | 6.6% | 6.8% | 7.1% | 7.0% | 6.8% |
| SG&A / Revenue | 19.3% | 19.6% | 20.7% | 20.7% | 21.0% | 22.9% |
| Effective tax rate | 16.5% | 19.3% | 18.5% | 18.8% | 46.3% | 15.2% |
| Return on assets | 17.1% | 14.9% | 13.3% | 15.3% | 10.0% | 13.6% |
| Return on equity | 23.5% | 21.0% | 21.7% | 23.2% | 16.4% | 24.9% |
| Return on invested capital | 21.2% | 19.2% | 16.6% | 19.7% | 13.8% | 18.8% |
| Liquidity | ||||||
| Current ratio | 3.44 | 2.59 | 3.12 | 2.80 | 1.73 | 2.53 |
| Quick ratio | 2.53 | 1.69 | 1.81 | 1.72 | 1.23 | 1.84 |
| Cash ratio | 1.19 | 0.26 | 0.30 | 0.40 | 0.32 | 0.77 |
| Leverage | ||||||
| Debt / Equity | 0.11 | 0.14 | 0.35 | 0.23 | 0.22 | 0.47 |
| Debt / Assets | 0.08 | 0.10 | 0.21 | 0.15 | 0.14 | 0.25 |
| Debt / EBITDA | 0.35 | 0.47 | 1.10 | 0.66 | 0.61 | 1.21 |
| Interest coverage | - | - | - | - | 37.7x | 20.1x |
| Equity multiplier | 1.37 | 1.41 | 1.63 | 1.52 | 1.64 | 1.84 |
| Liabilities / Assets | 0.27 | 0.29 | 0.39 | 0.34 | 0.39 | 0.46 |
| Efficiency | ||||||
| Asset turnover | 0.63 | 0.68 | 0.63 | 0.70 | 0.68 | 0.64 |
| Inventory turnover | 2.25 | 2.47 | 1.87 | 2.09 | 2.97 | 2.97 |
| Days sales outstanding | 67d | 65d | 61d | 59d | 70d | 59d |
| Days inventory outstanding | 162d | 148d | 195d | 175d | 123d | 123d |
| Days payable outstanding | 49d | 43d | 29d | 37d | 37d | 40d |
| Cash conversion cycle | 180d | 170d | 227d | 196d | 156d | 141d |
| Valuation | ||||||
| P / E | 27.1x | 27.7x | 35.9x | 39.6x | 76.1x | 45.0x |
| P / B | 6.4x | 5.8x | 7.8x | 9.2x | 12.5x | 11.2x |
| P / S | 7.4x | 6.0x | 7.6x | 8.6x | 11.3x | 9.5x |
| EV / EBITDA | 19.9x | 19.2x | 25.8x | 27.0x | 34.4x | 29.7x |
| Growth | ||||||
| Revenue growth (YoY) | 9.8% | 10.9% | 18.0% | 11.9% | 8.1% | 13.4% |
| Revenue CAGR (3y) | 12.9% | 13.6% | 12.6% | 11.1% | 11.0% | 12.7% |
| Revenue CAGR (5y) | 11.7% | 12.4% | 12.5% | 11.6% | 11.7% | 12.0% |
| Gross profit growth (YoY) | 15.1% | 12.7% | 16.4% | 10.1% | 7.1% | 11.8% |
| Operating income growth (YoY) | 27.7% | 16.6% | 13.2% | 10.7% | 11.6% | 39.8% |
| Net income growth (YoY) | 37.2% | 13.7% | 15.2% | 64.3% | -23.7% | 53.7% |
| EPS growth (YoY) | 37.4% | 13.6% | 14.9% | 63.6% | -24.1% | 52.5% |
| EPS CAGR (3y) | 21.5% | 28.8% | 12.6% | 23.7% | 13.9% | 21.2% |
| EPS CAGR (5y) | 17.4% | 19.8% | 22.7% | 17.2% | 5.4% | 11.6% |
| FCF growth (YoY) | 27.6% | 126.9% | 165.2% | -65.9% | -10.3% | 81.1% |
| FCF CAGR (5y) | 18.6% | 27.2% | 3.4% | -9.3% | 5.3% | 17.1% |
| Book value growth (YoY) | 22.7% | 17.8% | 22.9% | 16.5% | 15.6% | 20.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$5.15B totalSleep And Breathing Health$4.50B · 87.5%
Residential Care Software$641.44M · 12.5%
Product / service
$5.15B totalSleep And Breathing Health$4.50B · 87.5%
Residential Care Software$641.44M · 12.5%
Geographic
$7.81B totalUS$3.29B · 42.1%
Rest Of World$1.86B · 23.8%
U.S.Canada And Latin America$1.65B · 21.2%
Combined Europe Asia And Other Markets$1.01B · 12.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.25
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing RESMED INC against the 5 most active filers in the same SIC group.
Dividends
$2.40/share trailing 12 months · +13.2% YoY
| Ex-date | Per share |
|---|---|
| May 14, 2026 | $0.6000 |
| Feb 12, 2026 | $0.6000 |
| Nov 13, 2025 | $0.6000 |
| Aug 14, 2025 | $0.6000 |
| May 8, 2025 | $0.5300 |
| Feb 13, 2025 | $0.5300 |
| Nov 7, 2024 | $0.5300 |
| Aug 15, 2024 | $0.5300 |
| May 8, 2024 | $0.4800 |
| Feb 7, 2024 | $0.4800 |
| Nov 8, 2023 | $0.4800 |
| Aug 16, 2023 | $0.4800 |
| May 10, 2023 | $0.4400 |
| Feb 8, 2023 | $0.4400 |
| Nov 9, 2022 | $0.4400 |
| Aug 17, 2022 | $0.4400 |
| May 11, 2022 | $0.4200 |
| Feb 9, 2022 | $0.4200 |
| Nov 9, 2021 | $0.4200 |
| Aug 18, 2021 | $0.4200 |
| May 12, 2021 | $0.3900 |
| Feb 10, 2021 | $0.3900 |
| Nov 10, 2020 | $0.3900 |
| Aug 19, 2020 | $0.3900 |